News
Destiny Pharma plc – US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections
Brighton, United Kingdom – 25 January 2023 – Destiny Pharma…
STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference
Data demonstrates that STC-15, an oral METTL3 inhibitor,…
2022 Novo Holdings Seed Investments team Re-view/Business Update
Two successful exits – Syndesi and BioPhero
Four portfolio…
Neuraxpharm completes its presence in the Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg
Belgium team to expand under Country Manager, Dr Pierre-Hervé…
NeoPhore completes extension to Series B financing to further advance discovery pipeline
Scientific milestones achieved significantly ahead of schedule
Cambridge,…
Poolbeg announces strategic expansion of POLB 001 into oncology
Complements strong initial data from LPS challenge trial and…
STORM Therapeutics Expands R&D Leadership Team
Matthew Fyfe joins as Senior Vice President of Therapeutics
…
Novo Holdings participates in portfolio company Amolyt Pharma’s $138 million financing
Amolyt is developing therapeutic peptides for rare endocrine…
Novo Holdings invests in proteomics technology company, Evosep
COPENHAGEN, DENMARK — Novo Holdings, a leading international…
Positive Initial Data Analysis in POLB 001 LPS Challenge Trial
Early data read out indicates a successful LPS human challenge…
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V.,…
IOnctura Provides Development Update On First-In-Class Semi-Allosteric PI3Kδ Inhibitor Program
Updated clinical data demonstrates a prolonged and sustained…
MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine
Newly appointed CMO with more than 25 years’ experience…
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
Adcendo licenses Duality’s DITAC (Duality Immune Toxin…
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
Amsterdam and San Francisco / Houston / Singapore, 4 January…
ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in…
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Collaboration with OneThree Biotech identifies novel RSV treatments
First…
IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy
Funding will support iOnctura’s clinical program for IOA-289,…
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Statistically significant improvements in lung function, symptoms…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
